Prospective controlled study to evaluate cryocontact therapy for infantile haemangioma in preterm infants

Goelz, Rangmar; Moll, M.; Meisner, Christoph; Röcken, Martin; Poets, Christian F.; Moehrle, Matthias

doi:10.1136/archdischild-2013-304577

Cited by 6 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the high frequency of IH in preterm infants, there are no studies tailored especially to this high-risk group except for one small study using nitrogen-cooled cryocontact therapy (NCCT) exclusively in preterm infants 30. Thus, decisions can only be made in analogy to term infants, and therefore indications for treatment are mainly based on individual considerations.…”

Section: Indication For Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Incidence and treatment of infantile haemangioma in preterm infants

Goelz

Poets

2014

Arch Dis Child Fetal Neonatal Ed

Self Cite

View full text Add to dashboard Cite

Infantile haemangioma (IH) are vascular tumours with a unique growth dynamic, mostly absent at birth, growth in the first months followed by involution over several years, often resulting in residual skin changes. Immunehistologically, IH cells are exclusively glucose transporter protein-1 positive.The incidence of IH is increasing with decreasing gestational age, from 1-4% in term infants to 23% in those of <1000 g birth weight, with a female and Caucasian predominance. Discovery of systemic and topical beta blockers as an effective treatment option resulted in a rapid shift away from systemic steroids towards these drugs. For preterm infants, however, data on efficacy, pharmacokinetics and long-term safety are sparse or absent. Topical treatment without systemic side effects like cryotherapy may thus be an attractive alternative at an early growth stage (<10 mm). Indications for treatment with beta blockers, mostly propranolol systemically and timolol maleat 0.5% topically, are currently extrapolated from studies in older infants. Both seem effective, but adverse effects on sleep, circulation and metabolism are well described for propranolol. Long-term outcome data for either drug are missing. In conclusion, evidence on optimal IH treatment in preterms is lacking despite their high incidence; pharmacokinetic and clinical studies are warranted.

show abstract

Section: Indication For Treatmentmentioning

confidence: 99%

“…One prospective controlled study (quasi-randomised) could be identified,30 using NCCT (−196°C, 2–6 s application time) of IH (<10 mm in diameter) in infants ≤34 weeks GA compared with untreated intraindividual control-IH. NCCT led to fast regression with good cosmetic results.…”

Section: Therapymentioning

confidence: 99%

Incidence and treatment of infantile haemangioma in preterm infants

Goelz

Poets

2014

Arch Dis Child Fetal Neonatal Ed

Self Cite

View full text Add to dashboard Cite

show abstract

Interventions for infantile haemangiomas of the skin

Novoa

Baselga

Beltrán

et al. 2018

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

We found there to be a limited evidence base for the treatment of infantile haemangiomas: a large number of interventions and outcomes have not been assessed in RCTs.Our key results indicate that in the management of IH in children, oral propranolol and topical timolol maleate are more beneficial than placebo in terms of clearance or other measures of resolution, or both, without an increase in harms. We found no evidence of a difference between oral propranolol and topical timolol maleate with regard to reducing haemangioma size, but we are uncertain if there is a difference in safety. Oral propranolol is currently the standard treatment for this condition, and our review has not found evidence to challenge this. However, these results are based on moderate- to very low-quality evidence.The included studies were limited by small sample sizes and risk of bias in some domains. Future trials should blind personnel and participants; describe trials thoroughly in publications; and recruit a sufficient number of children to deduce meaningful results. Future trials should assess patient-reported outcomes, as well as objective outcomes of benefit, and should report adverse events comprehensively. Propranolol and timolol maleate require further assessment in RCTs of all types of IH, including those considered problematic, as do other lesser-used interventions and new interventions. All treatments should be compared against propranolol and timolol maleate, as beta blockers are approved as standard care.

show abstract

Cryocarboxy Surgery: A New Armamentarium in the Treatment of Infantile Hemangiomas of the Lips

Elmelegy,

Sadaka

2024

J. Maxillofac. Oral Surg.

View full text Add to dashboard Cite

Prospective controlled study to evaluate cryocontact therapy for infantile haemangioma in preterm infants

Cited by 6 publications

References 3 publications

Incidence and treatment of infantile haemangioma in preterm infants

Incidence and treatment of infantile haemangioma in preterm infants

Interventions for infantile haemangiomas of the skin

Cryocarboxy Surgery: A New Armamentarium in the Treatment of Infantile Hemangiomas of the Lips

Contact Info

Product

Resources

About